Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IMMUNO-FRIENDLY USE OF BCG CELL-WALL SKELETON REMARKABLY IMPROVES THESURVIVAL RATE OF VARIOUS CANCER-PATIENTS
Autore:
HAYASHI A; DOI O; AZUMA I; TOYOSHIMA K;
Indirizzi:
OSAKA MED CTR CANC & CARDIOVASC DIS,HIGASHINARI KU,1-3-3 NAKAMICHI OSAKA 5370025 JAPAN HOKKAIDO UNIV,SCH MED,KITA KU SAPPORO HOKKAIDO 060081 JAPAN
Titolo Testata:
Proceedings of the Japan Academy. Series B Physical and biological sciences
fascicolo: 3, volume: 74, anno: 1998,
pagine: 50 - 55
SICI:
0386-2208(1998)74:3<50:IUOBCS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADJUVANT IMMUNOTHERAPY; INTERFERON-GAMMA; CALMETTE-GUERIN; LUNG-CANCER;
Keywords:
CANCER IMMUNOTHERAPY; BCG-CWS; IMMUNE-FRIENDLY; IFN-GAMMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
A. Hayashi et al., "IMMUNO-FRIENDLY USE OF BCG CELL-WALL SKELETON REMARKABLY IMPROVES THESURVIVAL RATE OF VARIOUS CANCER-PATIENTS", Proceedings of the Japan Academy. Series B Physical and biological sciences, 74(3), 1998, pp. 50-55

Abstract

About 25 years ago, the study of cancer immunotherapy (IT) was done without paying due attention to patients' own immunogenicity, resultingin the failure in its clinical trials. This fact suggested that IT should be performed independently of other conventional chemo- and/or radiation therapies after removing as many tumor cells as possible. Between 1975 and 1997, total 235 cancer patients have been treated by IT with BCG-cell wall skeleton (CWS) alone, most just after surgical operations, and some after chemo- and/or radiation therapies. Appropriate dose (10 to 200 mu g) of BCG-CWS depending on the patients' biological responses, inoculated intracutaneously every 4 weeks, monitoring theirimmunogenicity with IFN-gamma induction test. In this pilot study, clinical effect of the immune-friendly use of BCG-CWS was shown most clearly in the effect of IFN-gamma induction and cancer stages on the survival rate. In fact this therapy was really effective for various kinds of cancers and for the patients in Stage I-III, but not for those inStage IV or in immunologically impaired state. Further in 84 postoperative primary lung cancer patients, especially in the group of 46 Stage III patients, the effect was statistically significant (X-2=8.546, p=0.0035). These clinical and statistical analyses suggest that the IT with BCG-CWS alone displays its effect on cancers attacking their lymphnode metastasis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 18:09:48